Abstract
| Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future Directions Spencer EA1, Dubinsky MC2. Pediatr Clin North Am. 2017 Dec;64(6):1309-1326. doi: 10.1016/j.pcl.2017.08.008. |
| Author information 1 Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine, Mount Sinai, Mt. Sinai Hospital, 1 Gustave L Levy Place, Box 1656, New York, NY 10029, USA. 2 Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine, Mount Sinai, Mt. Sinai Hospital, 1 Gustave L Levy Place, Box 1656, New York, NY 10029, USA. Electronic address: marla.dubinsky@mssm.edu. Abstract Clinical trials for the most effective drugs in the armamentarium of medications for inflammatory bowel disease(IBD) have shown only a 50-60% response rate, and this drops to 30% in maintenance. However, therapeutic drug monitoring (TDM) to adjust dosing to account for patient-specific characteristics, which has been shown to improve outcomes, was not utilized in these trials. This review will detail the development of TDM within the IBD space as it evolved from thiopurines to biologics and continues to evolve with loftier treat-to-target goals and more sophisticated dashboard systems. |
© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.
